Conference Reports for NATAP

Back

9th International Congress on Drug Therapy in HIV Infection November 9-13, 2008 Glasgow, Scotland     The Effect of Food on Ritonavir Bioavailability Following Administration of Ritonavir 100 mg Film-Coated Tablet in Healthy Adult Subjects - (12/09/08)   Population Pharmacokinetic/Pharmacodynamic Analyses of Lopinavir and Ritonavir in Subjects Receiving the Tablet Formulation - (12/09/08)   Pharmacokinetics of Once-Daily Etravirine (ETR) Without and With Once-Daily Darunavir/ Ritonavir (DRV/r) in Antiretroviral-Naïve HIV-1 Infected Adults - (12/09/08)   Adherence with Lopinavir/ritonavir (LPV/r) Tablet and Soft-Gel Capsule (SGC)-Based Antiretroviral Regimens and Predictors of Early Treatment Compliance - (12/08/08)   Metabolic Evaluation of Study M05-730 through Week (Wk) 48: Phase 3, Randomized, Open-Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naïve (ARV) HIV-1 Infected Subjects - (12/08/08)   Topics from the Drug Therapy in HIV Infection Meeting - written by Stephen Becker, MD - (12/08/08)   Switching from enfuvirtide to etravirine - efficacy results from the etravirine early access programme - (11/24/08)   Etravirine protects the activity of darunavir in the DUET trials - (11/24/08)   Antiretroviral treatment use and HIV RNA suppression rates for 941 European patients in the etravirine early access programme - (11/24/08)   Safety and tolerability of etravirine in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week results - (11/24/08)   Atazanavir Is Safe and Efficacious in HBV and HCV Coinfected Patients: Results of AI424138 (CASTLE) - (11/24/08)   The pharmacokinetic interaction between omeprazole and TMC278, an investigational NNRTI - (11/21/08)   Activity of etravirine on different HIV-1 subtypes: Week 48 data of the pooled DUET trials and in-vitro susceptibility in treatment-naïve patients - (11/21/08)   Simplification of Antiretroviral Therapy with Efavirenz/Emtricitabine/Tenofovir DF Single Tablet Regimen vs. Continued Antiretroviral Therapy in Suppressed, HIV-1-Infected Patients - (11/20/08)   Incidence of Infections in Treatment-experienced Patients Infected with R5 HIV-1 in the MOTIVATE Studies of Maraviroc in Combination with Optimized Background Therapy - (11/20/08)   Phase III TITAN Week 96 final analysis: efficacy/safety of darunavir/ritonavir versus lopinavir/ritonavir in lopinavir/ritonavir-naïve, treatment-experienced patients - (11/20/08)   Patient Reported Outcomes after Simplification to a Single Tablet Regimen of Efavirenz (EFV) / Emtricitabine (FTC) / Tenofovir DF (TDF) - (11/17/08)   Two HAART Interruption Studies Presented at Glasgow HIV Conference Nov 10 2008 - (11/17/08)   Raltegravir Clinical Efficacy Against B Subtype and Non-B Subtype HIV-1 is Similar - (11/17/08)   Efficacy and Safety (malignancies) of Maraviroc in Treatment-Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies - (11/17/08)   Better CD4 Gains on Antiretrovirals Linked to Clearance of Cancer-Causing HPV - Written by Mark Mascolini - (11/17/08)   Risks and Benefits of 5 Days On/2 Days Off in the FOTO Study - Written by Mark Mascolini - (11/17/08)   No Evidence of Virologic Benefit With Higher Lopinavir Dose for Children - Written by Mark Mascolini - (11/17/08)   More Time With Sub-500 Load on First Regimen Cuts Risk of Second-Line Failure - Written by Mark Mascolini - (11/17/08)   Lipid effects in the ARTEMIS and TITAN trials: effects of demographics, HIV disease stage, treatment arm and lipid-lowering drugs - (11/17/08)   OI and Death Rates With Low CD4s and High vs Low Viral Load - Undetectable Viral Load Matters - Written by Mark Mascolini - (11/13/08)   Failure Rate Twice Higher With Second-Line Versus First-Line HAART - Written by Mark Mascolini - (11/13/08)   Lower Failure and Resistance Rates With Darunavir Than Lopinavir at 96 Weeks of TITAN - Written by Mark Mascolini - (11/13/08)   Slow CD4 Gain With HAART Raises AIDS Rate 5 Times in Virologic Responders - Written by Mark Mascolini - (11/13/08)   Cardiovascular disease; HIV, ART, immunodeficiency, pro-inflammation and other factors - (11/13/08)   Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: Week 96 data from TMC278-C204 - (11/13/08)   Efficacy and Safety by Baseline HIV RNA and CD4 Count in Treatment-Naïve Patients Treated With Atazanavir/RTV and Lopinavir/RTV in the CASTLE Study - (11/13/08)   Efficacy and safety of switching from Lopinavir/r to Atazanavir/r in suppressed patients receiving a LPV/r containing HAART: ATAZIP 96 weeks results - (11/13/08)   High HIV Load Stymies Calcium Deposition in Bone-Forming Cells - Written by Mark Mascolini - (11/12/08)   Response Rate, Resistance, and Side Effects After 96 Weeks of TMC278 - Written by Mark Mascolini - (11/12/08)   D:A:D Cohort Group Offers Tool to Predict Short-Term Diabetes With HIV - Written by Mark Mascolini - (11/12/08)   D:A:D Cohort Group Offers Tool to Predict Short-Term Diabetes With HIV - Written by Mark Mascolini - (11/12/08)   Will Etravirine Work Once Daily--With Once-Daily Darunavir? - Written by Mark Mascolini - (11/12/08)   Salvage With Raltegravir, Etravirine, and Darunavir Works Fast in Small Case Series - Written by Mark Mascolini - (11/12/08)   Potent Multidrug Salvage Without PIs or NRTIs: Raltegravir + Maraviroc + Etravirine - Written by Mark Mascolini - (11/12/08)   CD4 Gains During Suppressive Therapy Differ by Pretreatment T-Cell Count - Written by Mark Mascolini - (11/12/08)   Three Cohorts See No RNA Disadvantage With Abacavir/Lamivudine - Written by Mark Mascolini - (11/12/08)   Renal Tubule Damage With Tenofovir Despite Normal Glomerular Function - Written by Mark Mascolini - (11/12/08)   Inflammation and Coagulation Markers Askew in Children With Higher HIV RNA - Written by Mark Mascolini - (11/12/08)